186 related articles for article (PubMed ID: 27029001)
1. Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins.
Asp N; Kvalvaag A; Sandvig K; Pust S
Oncotarget; 2016 May; 7(18):25443-60. PubMed ID: 27029001
[TBL] [Abstract][Full Text] [Related]
2. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
3. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ezrin causes PKCα-mediated internalization of erbb2/HER2 tyrosine kinase in breast cancer cells.
Jeong J; Choi J; Kim W; Dann P; Takyar F; Gefter JV; Friedman PA; Wysolmerski JJ
J Biol Chem; 2019 Jan; 294(3):887-901. PubMed ID: 30463939
[TBL] [Abstract][Full Text] [Related]
5. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
6. DEPTOR stabilizes ErbB2 to promote the proliferation and survival of ErbB2-positive breast cancer cells.
Bi Y; Chen X; Wei B; Wang L; Gong L; Li H; Xiong X; Zhao Y
Theranostics; 2021; 11(13):6355-6369. PubMed ID: 33995662
[No Abstract] [Full Text] [Related]
7. Flotillins as regulators of ErbB2 levels in breast cancer.
Pust S; Klokk TI; Musa N; Jenstad M; Risberg B; Erikstein B; Tcatchoff L; Liestøl K; Danielsen HE; van Deurs B; Sandvig K
Oncogene; 2013 Jul; 32(29):3443-51. PubMed ID: 22869152
[TBL] [Abstract][Full Text] [Related]
8. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
9. Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer.
Wolfson E; Goldenberg M; Solomon S; Frishberg A; Pinkas-Kramarski R
Oncotarget; 2016 Oct; 7(40):65320-65334. PubMed ID: 27542246
[TBL] [Abstract][Full Text] [Related]
10. Identification of an HSP90 modulated multi-step process for ERBB2 degradation in breast cancer cells.
Castagnola P; Bellese G; Birocchi F; Gagliani MC; Tacchetti C; Cortese K
Oncotarget; 2016 Dec; 7(51):85411-85429. PubMed ID: 27863425
[TBL] [Abstract][Full Text] [Related]
11. Ezrin-radixin-moesin (ERM)-binding phosphoprotein 50 organizes ERM proteins at the apical membrane of polarized epithelia.
Morales FC; Takahashi Y; Kreimann EL; Georgescu MM
Proc Natl Acad Sci U S A; 2004 Dec; 101(51):17705-10. PubMed ID: 15591354
[TBL] [Abstract][Full Text] [Related]
12. The Role of CD44 and ERM Proteins in Expression and Functionality of P-glycoprotein in Breast Cancer Cells.
Pokharel D; Padula MP; Lu JF; Jaiswal R; Djordjevic SP; Bebawy M
Molecules; 2016 Mar; 21(3):290. PubMed ID: 26938523
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells.
Liu B; Ordonez-Ercan D; Fan Z; Edgerton SM; Yang X; Thor AD
Int J Cancer; 2007 May; 120(9):1874-82. PubMed ID: 17266042
[TBL] [Abstract][Full Text] [Related]
14. MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistance.
Paulson AK; Linklater ES; Berghuis BD; App CA; Oostendorp LD; Paulson JE; Pettinga JE; Melnik MK; Vande Woude GF; Graveel CR
Mol Cancer Res; 2013 Sep; 11(9):1112-21. PubMed ID: 23825050
[TBL] [Abstract][Full Text] [Related]
15. The Na+/H+ exchanger NHE1, but not the Na+, HCO3(-) cotransporter NBCn1, regulates motility of MCF7 breast cancer cells expressing constitutively active ErbB2.
Lauritzen G; Stock CM; Lemaire J; Lund SF; Jensen MF; Damsgaard B; Petersen KS; Wiwel M; Rønnov-Jessen L; Schwab A; Pedersen SF
Cancer Lett; 2012 Apr; 317(2):172-83. PubMed ID: 22120673
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
17. Re-defining ERM function in lymphocyte activation and migration.
Parameswaran N; Gupta N
Immunol Rev; 2013 Nov; 256(1):63-79. PubMed ID: 24117813
[TBL] [Abstract][Full Text] [Related]
18. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
19. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
20. ERM proteins in cancer progression.
Clucas J; Valderrama F
J Cell Sci; 2014 Jan; 127(Pt 2):267-75. PubMed ID: 24421310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
